	US 12,134,663 B2
	Cationic peptides for activating Lck
Michael Valentine Agrez, New South Wales (AU)
Assigned to Interk Peptide Therapeutics Limited, New South Wales (AU)
Appl. No. 17/055,250
Filed by Interk Peptide Therapeutics Limited, New South Wales (AU)
PCT Filed May 15, 2019, PCT No. PCT/AU2019/050462 § 371(c)(1), (2) Date Nov. 13, 2020, PCT Pub. No. WO2019/218015, PCT Pub. Date Nov. 21, 2019.
Claims priority of application No. 2018901672 (AU), filed on May 15, 2018.
Prior Publication US 2021/0380639 A1, Dec. 9, 2021
Int. Cl. C07K 7/08 (2006.01); A61K 38/00 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); C07K 7/06 (2006.01)

CPC C07K 7/08 (2013.01) [A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 7/06 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01)]

1 Claim

1. A peptide for activating Lck comprising a peptide amino acid sequence selected from RSKAKNPLYR-RRRRRRRR (SEQ ID NO: 24) or rskaknplyr-rrrrrrrr (SEQ ID NO: 129).